Teleflex Incorporated (NYSE:TFX) released its earnings results on Thursday. The medical technology company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.13, Bloomberg Earnings reports. The firm had revenue of $528.60 million during the quarter, compared to the consensus estimate of $518.98 million. Teleflex had a return on equity of 13.73% and a net margin of 14.82%. The company’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.89 EPS. Teleflex updated its FY17 guidance to $8.20-8.35 EPS.

Shares of Teleflex (TFX) traded down 1.21% during mid-day trading on Friday, hitting $214.26. The company had a trading volume of 386,731 shares. The company has a market capitalization of $9.64 billion, a PE ratio of 44.47 and a beta of 1.05. Teleflex has a one year low of $136.53 and a one year high of $217.97. The company’s 50-day moving average is $207.61 and its 200 day moving average is $195.00.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Tuesday, August 15th will be given a dividend of $0.34 per share. The ex-dividend date is Friday, August 11th. This represents a $1.36 annualized dividend and a dividend yield of 0.63%. Teleflex’s dividend payout ratio is currently 26.00%.

In other news, VP John Deren sold 2,246 shares of Teleflex stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $194.07, for a total value of $435,881.22. Following the completion of the transaction, the vice president now directly owns 3,989 shares in the company, valued at $774,145.23. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $199.93, for a total value of $39,986.00. Following the completion of the transaction, the director now owns 8,080 shares of the company’s stock, valued at $1,615,434.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,546 shares of company stock valued at $2,079,856. 2.39% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Asset Planning Services Ltd. acquired a new position in Teleflex during the first quarter valued at approximately $116,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Teleflex during the first quarter valued at approximately $155,000. OLD Mutual Customised Solutions Proprietary Ltd. boosted its position in Teleflex by 200.0% in the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock valued at $174,000 after buying an additional 600 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Teleflex during the second quarter valued at approximately $200,000. Finally, Harvey Capital Management Inc. acquired a new position in Teleflex during the second quarter valued at approximately $207,000. Institutional investors own 92.95% of the company’s stock.

A number of research firms have recently weighed in on TFX. Jefferies Group LLC reiterated a “buy” rating and set a $230.00 target price on shares of Teleflex in a research report on Thursday. Needham & Company LLC reiterated a “buy” rating on shares of Teleflex in a research report on Friday. BidaskClub downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Zacks Investment Research downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Leerink Swann upped their target price on Teleflex from $215.00 to $220.00 and gave the company a “market perform” rating in a research report on Friday, June 9th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $221.17.

COPYRIGHT VIOLATION WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/05/teleflex-incorporated-tfx-releases-earnings-results-beats-expectations-by-0-13-eps.html.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.